



Anylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY 1

Last Trade:	83.54
Trade Time:	4:00 PM ET 07.24.2017
Change:	1.52 (1.853%)
Day Range	80.67 - 83.73
52-Week Range	31.38 - 86.92
Volume	723,740
Market Cap. (\$M)	7,643.075
Shares Out (M)	91.490

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Anylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STArS): genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases. These novel therapeutics carry the potential to transform the lives of patients who have limited or inadequate treatment options. Founded in 2002, Anylam is delivering on a bold vision to turn scientific possibility into a reality, with a robust discovery platform and deep pipeline of investigational medicines, including three product candidates that are i ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 07.10.2017 [Alnylam and Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors](#)
- 07.07.2017 [Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors](#)
- 06.26.2017 [Alnylam and Sanofi Genzyme to Present New Clinical Trial Results at the International Society of Thrombosis and Haemostasis \(ISTH\) Congress](#)
- 06.26.2017 [Alnylam Reports New Positive Clinical Results for Givosiran \(ALN-AS1\), an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias](#)
- 06.19.2017 [Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- 02.15.2017 [Annual Report \(10-K\)](#)
- 03.17.2017 [Definitive Proxy Statement](#)
- 05.05.2017 [Quarterly Report \(10-Q\)](#)
- 11.03.2016 [Quarterly Report \(10-Q\)](#)
- 08.04.2016 [Quarterly Report \(10-Q\)](#)

